Evaluation of the potential interaction between tofacitinib and drugs that undergo renal tubular secretion using metformin, an in vivo marker of renal organic cation transporter 2

Clinical Pharmacology in Drug Development

Volumn 3, Issue 6, 2014, Pages 499-507

  Klamerus, Karen J ^a   Alvey, Christine ^a   Li, Lei ^a,b   Feng, Bo ^a   Wang, Rong ^a   Kaplan, Irina ^a   Shi, Haihong ^a   Dowty, Martin E ^a   Krishnaswami, Sriram ^a  

^a PFIZER INC   (United States)

^b NONE   (United States)

Author keywords

Drug drug interactions; Metformin; Organic cation transporter; Tofacitinib; Tubular secretion

Indexed keywords

METFORMIN; MULTIDRUG AND TOXIN EXTRUSION PROTEIN 1; ORGANIC CATION TRANSPORTER 2; TOFACITINIB; JANUS KINASE INHIBITOR; PIPERIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; PYRROLE DERIVATIVE; SLC22A2 PROTEIN, HUMAN;

ABDOMINAL DISTENSION; ADULT; ARTICLE; BLOOD ANALYSIS; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; EMBRYO; FLATULENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CLEARANCE; KIDNEY TUBULE EXCRETION; MALE; MAXIMUM PLASMA CONCENTRATION; MORNING DOSAGE; MUSCULOSKELETAL PAIN; NORMAL HUMAN; OCT2 GENE; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PLASMA CONCENTRATION-TIME CURVE; PRIORITY JOURNAL; SINGLE DRUG DOSE; TIME TO MAXIMUM PLASMA CONCENTRATION; UPPER ABDOMINAL PAIN; URINALYSIS; VOMITING; ANTAGONISTS AND INHIBITORS; AREA UNDER THE CURVE; BELGIUM; BLOOD; CLINICAL TRIAL; DRUG INTERACTION; FEMALE; GENETIC TRANSFECTION; GENETICS; HEK293 CELL LINE; KIDNEY TUBULE; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION; SECRETION (PROCESS); URINARY EXCRETION; URINE; YOUNG ADULT;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BELGIUM; DRUG INTERACTIONS; FEMALE; HEALTHY VOLUNTEERS; HEK293 CELLS; HUMANS; JANUS KINASE INHIBITORS; KIDNEY TUBULES; MALE; METFORMIN; MIDDLE AGED; ORGANIC CATION TRANSPORTER 2; PIPERIDINES; PYRIMIDINES; PYRROLES; RENAL ELIMINATION; TRANSFECTION; YOUNG ADULT;

EID: 84906835193     PISSN: 2160763X     EISSN: 21607648     Source Type: Journal    
DOI: 10.1002/cpdd.120     Document Type: Article

References (28)

1. Meyer DM, Jesson MI, Li X, et al. Anti-inflammatory activity and neutrophil reductions mediated by the JAK1/JAK3 inhibitor, CP-690, 550, in rat adjuvant-induced arthritis. J Inflamm (Lond). 2010; 7:41.
2. Dowty ME, Lin J, Ryder TF, et al. The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans. Drug Metab Dispos. 2014; 42:759-773.
3. Gupta P, Alvey C, Wang R, et al. Lack of effect of tofacitinib (CP-690, 550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: Confirmation of in vitro data. Br J Clin Pharmacol. 2012; 74:109-115.
4. Gupta P, Chow V, Wang R, et al. Evaluation of the effect of fluconazole and ketoconazole on the pharmacokinetics of tofacitinib in healthy adult subjects. Clin Pharm Drug Dev. 2014; 3:72-77.
5. Krishnaswami S, Kudlacz E, Wang R, Chan G. A supratherapeutic dose of the Janus kinase inhibitor tasocitinib (CP-690, 550) does not prolong QTc interval in healthy participants. J Clin Pharmacol. 2010; 51:1256-1263.
6. Krishnaswami S. Pharmacokinetic profile of CP-690, 550 in de novo renal allograft recipients. Suppl Transplant. 2008; 86:414.
7. Cohen S, Zwillich SH, Chow V, LaBadie RR, Wilkinson B. Co-administration of the JAK inhibitor CP-690, 550 and methotrexate is well tolerated in patients with rheumatoid arthritis without need for dose adjustment. Br J Clin Pharmacol. 2010; 69:143-151.
8. Tan H, Gupta P, Harness J, et al. Dose-response and pharmacokinetics of tofacitinib (CP-690, 550), an oral janus kinase inhibitor, in the treatment of chronic plaque psoriasis. CPT Pharmacometrics Syst Pharmacol. 2013; 2:e44.
9. Gao X, Krishnaswami S, Mukherjee A. A population pharmacokinetic model from a Phase 2 study of tofacitinib (CP-690, 550), an oral Janus kinase inhibitor, in active ulcerative colitis [abstract]. Dig Dis Week. 2012.
10. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010; 9:215-236.
11. Tzvetkov MV, Vormfelde SV, Balen D, et al. The effects of genetic polymorphisms in the organic cation transporters OCT1, OCT2, and OCT3 on the renal clearance of metformin. Clin Pharmacol Ther. 2009; 86:299-306.
12. Sirtori CR, Franceschini G, Galli-Kienle M, et al. Disposition of metformin (N, N-dimethylbiguanide) in man. Clin Pharmacol Ther. 1978; 24:683-693.
13. Tucker GT, Casey C, Phillips PJ, Connor H, Ward JD, Woods HF. Metformin kinetics in healthy subjects and in patients with diabetes mellitus. Br J Clin Pharmacol. 1981; 12:235-246.
14. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Genetic variation in the multidrug and toxin extrusion 1 transporter protein influences the glucose-lowering effect of metformin in patients with diabetes: A preliminary study. Diabetes. 2009; 58:745-749.
15. Chen L, Takizawa M, Chen E, et al. Genetic polymorphisms in organic cation transporter 1 (OCT1) in Chinese and Japanese populations exhibit altered function. J Pharmacol Exp Ther. 2010; 335:42-50.
16. Meyer zu, Schwabedissen HE, Verstuyft C, Kroemer HK, Becquemont L, Kim RB. Human multidrug and toxin extrusion 1 (MATE1/SLC47A1) transporter: functional characterization, interaction with OCT2 (SLC22A2), and single nucleotide polymorphisms. Am J Physiol Renal Physiol. 2010; 298:F997-F1005.
17. Minematsu T, Giacomini KM. Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins. Mol Cancer Ther. 2011; 10:531-539.
18. Kroetz DL, Yee SW, Giacomini KM. The pharmacogenomics of membrane transporters project: research at the interface of genomics and transporter pharmacology. Clin Pharmacol Ther. 2010; 87:109-116.
19. Breyer MD, Qi Z. Better nephrology for mice-and man. Kidney Int. 2010; 77:487-489.
20. He Y, Wong AY, Chan EW, et al. Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2013; 14:298.
21. Shu Y, Brown C, Castro RA, et al. Effect of genetic variation in the organic cation transporter 1, OCT1, on metformin pharmacokinetics. Clin Pharmacol Ther. 2008; 83:273-280.
22. Becker ML, Visser LE, van Schaik RH, Hofman A, Uitterlinden AG, Stricker BH. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response. Pharmacogenet Genomics. 2010; 20:38-44.
23. Centers for Disease Control and Prevention. Good laboratory practices for molecular genetic testing for heritable diseases and conditions. MWMR Recomm Rep. 2009; 58:43.
24. Marathe PH, Arnold ME, Meeker J, Greene DS, Barbhaiya RH. Pharmacokinetics and bioavailability of a metformin/glyburide tablet administered alone and with food. J Clin Pharmacol. 2000; 40:1494-1502.
25. Atanasova I, Bozhinova K, Todorova D, Terziivanov D. Pharmacokinetics and comparative bioavailability of two metformin formulations after single-dose administration in healthy subjects. Clin Drug Investig. 2003; 23:743-749.
26. Zamek-Gliszczynski MJ, Hoffmaster KA, Tweedie DJ, Giacomini KM, Hillgren KM. Highlights from the international transporter consortium second workshop. Clin Pharmacol Ther. 2012; 92:553-556.
27. Lawendy N, Krishnaswami S, Wang R, et al. Effect of CP-690, 550, an orally active janus kinase inhibitor, on renal function in healthy adult volunteers. J Clin Pharmacol. 2009; 49:423-429.
28. Kremer JM, Cohen S, Wilkinson BE, et al. A phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690, 550) versus placebo in combination with background methotrexate in patients with active rheumatoid arthritis and an inadequate response to methotrexate alone. Arthritis Rheum. 2012; 64:970-981.